{"Title": "Evolution and cancer medicine-Transformative insights", "Year": 2017, "Source": "Nat. Rev. Clin. Oncol.", "Volume": "14", "Issue": 12, "Art.No": null, "PageStart": 709, "PageEnd": 710, "CitedBy": 2, "DOI": "10.1038/nrclinonc.2017.121", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034591193&origin=inward", "Abstract": "\u00a9 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.Few clinical trials incorporate studies of evolutionary cancer biology, despite the frequent emergence of acquired resistance to anticancer therapies. This problem motivated the first CRUK Marshall Symposium on Cancer Evolution in May 2017, which provided a forum for evolutionary and ecological theorists, cancer biologists, and clinicians to consider how evolutionary biology might inform improvements in cancer medicine. Herein, we discuss the key themes and opportunities for the future.", "AuthorKeywords": null, "IndexKeywords": ["Cell Transformation, Neoplastic", "Evolution, Molecular", "Genomic Instability", "Humans", "Neoplasms", "Tumor Microenvironment"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-85034591193", "SubjectAreas": [["Oncology", "MEDI", "2730"]], "AuthorData": {"35551546000": {"Name": "Sahai E.", "AuthorID": "35551546000", "AffiliationID": "60107285", "AffiliationName": "Tumour Cell Biology Laboratory, Francis Crick Institute"}, "7005912775": {"Name": "Swanton C.", "AuthorID": "7005912775", "AffiliationID": "60107285", "AffiliationName": "Translational Cancer Therapeutics Laboratory, Francis Crick Institute"}}}